Eikon Therapeutics

EIKN13F as of Jun 30, 2026 · next update ~Nov 14

Limited coverage

Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.

Who's buying EIKN

Top funds mostly added to Eikon Therapeutics in Q2 (Apr⁠–⁠Jun)

Buying:

Funds1Insiders5Congress

Top funds
1 of 1 bought more, 0 sold some. Largest: Polen Capital Management, $466K (0% of its portfolio).
Insiders
5 insiders bought, 0 sales in 12 months.
Congress
No trades disclosed in the last 12 months.

1 fund$466,433 held0.0% avg. weightQ2: 1 bought / 0 sold

13F reports are a snapshot as of Jun 30, 2026; funds may have traded since.

Share price · market data, not from 13F reports

Q2 2026

Insider trades (Form 4)

Last 2 years · 6 filings

Net buying$52.15M

Date	Insider	Type	Shares	Price	Value
Sep 3, 2026	Column Group IV Gp, LP 10% Owner	Bought	89,200	$11.56	$1.03M
Feb 6, 2026	Column Group IV Gp, LP 10% Owner	Bought	2,117,760	$18.00	$38.12M
Feb 4, 2026	Foresite Capital Management Iv, LLC 10% Owner	Bought	55,555	$18.00	$1000K
Feb 4, 2026	Kenneth C Frazier Director	Bought	111,111	$18.00	$2.00M
Feb 4, 2026	Josh Wolfe Director & 10% Owner	Bought	277,776	$18.00	$5.00M
Feb 4, 2026	Lux Venture Partners V, LLC 10% Owner	Bought	277,776	$18.00	$5.00M